Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases

BACKGROUND: PCSK9 inhibition is a new powerful cholesterol-lowering strategy. Recently, it was reported that CETP inhibitors influence PCSK9 levels as an off-target effect. We explored the relationship between circulating PCSK9 levels and CETP activity in patients with metabolic disease who were not...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cardiovasc Diabetol
Autors principals: Girona, Josefa, Ibarretxe, Daiana, Plana, Nuria, Guaita-Esteruelas, Sandra, Amigo, Nuria, Heras, Mercedes, Masana, Luis
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2016
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4973048/
https://ncbi.nlm.nih.gov/pubmed/27488210
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-016-0428-z
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars